13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001381843
Total reported value
$371.7M
$371.7M
36 檔
23.8%
During the Q3 2024 filing period, Atle Fund Management AB (CIK: 0001381843) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $371.7M across 36 reported positions.
In Q3 2024, Atle Fund Management AB displayed an active expansion posture, initiating 3 new positions and adding to 28 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 12.73% | +0.95% | +12.60% | |
| 2 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 9.75% | -0.90% | EXIT | |
| 3 | MRK | Merck & Co. Inc. | Stock-Healthcare | 8.26% | -0.85% | +37.22% | |
| 4 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 6.40% | -0.91% | +13.13% | |
| 5 | AMGN | Amgen Inc | Stock-Healthcare | 4.39% | -2.81% | EXIT | |
| 6 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.18% | -1.18% | -0.36% | |
| 7 | ABBV | Abbvie Inc | Stock-Healthcare | 4.13% | +1.00% | +24.90% | |
| 8 | SYK | Stryker CORP | Stock-Healthcare | 3.98% | -0.53% | +17.40% | |
| 9 | COR | Cencora Inc | Stock-Healthcare | 3.87% | +0.24% | +20.53% | |
| 10 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 3.71% | -1.05% | +12.57% | |
| 11 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 3.47% | — | +1.96% | |
| 12 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.28% | +0.77% | +156.48% | |
| 13 | ALKS | Alkermes plc | Stock-Healthcare | 3.11% | +0.35% | +243.91% | |
| 14 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.91% | — | +135.98% | |
| 15 | HRMY | Harmony Biosciences Holdings | Stock-Other | 2.86% | — | +335.17% | |
| 16 | UFPT | Ufp Technologies Inc | Stock-Other | 2.69% | — | +84.16% | |
| 17 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.54% | +0.15% | +83.94% | |
| 18 | DXCM | Dexcom Inc | Stock-Healthcare | 1.69% | +0.45% | +55.89% | |
| 19 | ACLXGBX | Arcellx Inc | Stock-Other | 1.58% | — | +78.83% | |
| 20 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.56% | -0.10% | +103.22% | |
| 21 | CAH | Cardinal Health Inc | Stock-Healthcare | 1.43% | -0.03% | — | |
| 22 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.38% | — | +85.87% | |
| 23 | ✓ | Merus N V | Stock-Other | 1.19% | — | +64.37% | |
| 24 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.13% | -0.16% | — | |
| 25 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.08% | +0.49% | +83.37% | |
| 26 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.89% | — | — | |
| 27 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.79% | — | +127.35% | |
| 28 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.79% | +0.21% | +20.70% | |
| 29 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.75% | — | +95.64% | |
| 30 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.67% | — | +77.94% | |
| 31 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.64% | -1.34% | — | |
| 32 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.63% | -0.71% | EXIT | |
| 33 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.48% | — | +191.30% | |
| 34 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.39% | — | — | |
| 35 | CABA | Cabaletta Bio Inc | Stock-Other | 0.37% | — | +162.00% | |
| 36 | PHVS | Pharvaris N.V. | Stock-Other | 0.30% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | HRMY | Harmony Biosciences Holdings | +2.2% | +335.17% | Add |
| 2 | ALKS | Alkermes plc | +2.1% | +243.91% | Add |
| 3 | ITCIEUR | Intra-cellular Therapies Inc | +1.4% | +135.98% | Add |
| 4 | NBIX | Neurocrine Biosciences Inc | +1.3% | +156.48% | Add |
| 5 | UFPT | Ufp Technologies Inc | +1.1% | +84.16% | Add |
| 6 | MIRM | Mirum Pharmaceuticals Inc | +1% | +83.94% | Add |
| 7 | SMMT | Summit Therapeutics Inc | +0.9% | NEW | New buy |
| 8 | ACLXGBX | Arcellx Inc | +0.8% | +78.83% | Add |
| 9 | SLNOEUR | Soleno Therapeutics Inc | +0.6% | NEW | New buy |
| 10 | AM6 | Amicus Therapeutics Inc | +0.5% | +85.87% | Add |
| 11 | ABBV | Abbvie Inc | +0.4% | +24.90% | Add |
| 12 | MREO | Mereo Biopharma Group Pl-adr | +0.4% | NEW | New buy |
| 13 | IONS | Ionis Pharmaceuticals Inc | +0.4% | +103.22% | Add |
| 14 | IMCR | Immunocore Holdings Plc-adr | +0.3% | +127.35% | Add |
| 15 | AUTL | Autolus Therapeutics PLC | +0.3% | +95.64% | Add |
| 16 | ✓ | Mersana Therapeutics Inc | +0.3% | +191.30% | Add |
| 17 | NAMS | NewAmsterdam Pharma Company N.V. | +0.2% | +83.37% | Add |
| 18 | ✓ | Merus N V | +0.1% | +64.37% | Add |
| 19 | CABA | Cabaletta Bio Inc | +0.1% | +162.00% | Add |
| 20 | KRYS | Krystal Biotech Inc | -0.1% | +20.70% | Add |
| 21 | UNH | Unitedhealth Group Inc | -0.1% | +12.03% | Add |
| 22 | PHVS | Pharvaris N.V. | -0.1% | — | Unchanged |
| 23 | TMO | Thermo Fisher Scientific Inc | -0.2% | +13.13% | Add |
| 24 | SYK | Stryker CORP | -0.2% | +17.40% | Add |
| 25 | BBIO | Bridgebio Pharma Inc | -0.2% | — | Unchanged |
| 26 | CAH | Cardinal Health Inc | -0.2% | — | Unchanged |
| 27 | MRK | Merck & Co. Inc. | -0.3% | +37.22% | Add |
| 28 | COR | Cencora Inc | -0.3% | +20.53% | Add |
| 29 | MGNX | Macrogenics Inc | -0.4% | EXIT | Sold out |
| 30 | CRBP | Corbus Pharmaceuticals Holdi | -0.4% | +77.94% | Add |
| 31 | MORFUSD | Morphic Holding Inc | -0.4% | EXIT | Sold out |
| 32 | VRTX | Vertex Pharmaceuticals Inc | -0.6% | +12.57% | Add |
| 33 | DXCM | Dexcom Inc | -0.7% | +55.89% | Add |
| 34 | BSX | Boston Scientific CORP | -0.8% | -0.36% | Trim |
| 35 | AMGN | Amgen Inc | -0.9% | +4.99% | Add |
| 36 | OPCH | Option Care Health Inc | -0.9% | EXIT | Sold out |
| 37 | EW | Edwards Lifesciences CORP | -0.9% | — | Unchanged |
| 38 | REGN | Regeneron Pharmaceuticals | -1% | +1.96% | Add |
| 39 | MOH | Molina Healthcare Inc | -1.7% | EXIT | Sold out |
| 40 | IQV | Iqvia Holdings Inc | -1.8% | EXIT | Sold out |
| 41 | LLY | Eli Lilly & Co | -2.3% | +12.60% | Add |
According to official SEC Form 13F filings, Atle Fund Management AB reported a total U.S. public equity portfolio value of $371.7M across 36 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, UNH, MRK) accounted for 23.8% of total reported equity market value during Q3 2024.
Top New Position Initiated
SMMT
市值: $1.9M
Top Position Liquidated / Trimmed
IQV
前期市值: $3.0M
During Q3 2024, Atle Fund Management AB's top holdings by market value included LLY (12.7%)、UNH (9.8%)、MRK (8.3%). The largest single position, LLY, represented 12.7% of total portfolio value.
In Q3 2024, Atle Fund Management AB made 37 total portfolio adjustments, initiating 3 new buys, adding to 28 positions, trimming 1 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.